The severe EPS miss and guidance cut are bearish, but the stock may find support if the market focuses on the H2 return to positive EBITDA and the ~$250M exit run rate. Watch for Q3 2026 results and any updates on the XYOSTED® launch and Women's Health progress to validate the turnaround narrative.
Price Chart
Executive Summary
LifeMD reported Q2 2026 revenue of $47.3M (within guidance of $47M-$50M) but a significant EPS miss of -$0.16 vs consensus of -$0.04, a -255.6% surprise. The company lowered full-year 2026 revenue guidance to $205.5M-$212.5M (from $220M-$230M) and adjusted EBITDA guidance to -$6M to breakeven (from $12M-$17M), citing the transition from compounded to branded GLP-1 therapies. Despite the miss, management expects a return to positive adjusted EBITDA in H2 2026 and an exit revenue run rate of ~$250M, which may provide a floor for the stock near-term.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $47.3M, within guidance of $47M-$50M but down from $49.0M YoY
- EPS of -$0.16 missed consensus of -$0.04 by 255.6%
- Full-year 2026 revenue guidance lowered to $205.5M-$212.5M from $220M-$230M
- Full-year 2026 adjusted EBITDA guidance lowered to -$6M to breakeven from $12M-$17M
- Gross margin expanded ~280 bps YoY to ~89%
- Active subscribers grew 20% YoY to ~356,000; Weight Management subscribers ~108,000
- Cash of $25.1M, no debt, and $30M undrawn revolver
- Expects return to positive adjusted EBITDA in H2 2026 and Q4 exit revenue run rate of ~$250M
Financial Impact
Q2 revenue $47.3M (down 3.5% YoY), EPS -$0.16 (miss by $0.12), FY guidance cut by $14.5M-$17.5M on revenue and $18M-$23M on adjusted EBITDA
Risk Factors
- Continued transition from compounded to branded GLP-1s may pressure near-term profitability
- Lowered guidance signals slower growth and margin compression
- Execution risk on H2 2026 EBITDA and revenue run rate targets
- Litigation costs from class action may persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339867 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | SC 13G/A | $2.79 | awaiting T+20 | — | $2.13 (−23.69%) |
Sep 22, 2026 4w ago | Press Release | $3.05 $2.14 | ▼ −29.84% | ▼ −30.52% | $2.13 (−30.20%) |
Aug 5, 2026 11w ago | Press Release | $3.40 $3.05 | ▲ +10.29% | ▲ +10.89% | $2.13 (+37.38%) |
Apr 27, 2026 26w ago | Press Release | $4.57 $4.24 | ▼ −7.22% | ▼ −12.18% | $2.13 (−53.41%) |
Mar 31, 2026 30w ago | Press Release | $3.61 $4.43 | ▲ +22.71% | ▲ +13.29% | $2.13 (−41.02%) |
Mar 24, 2026 30w ago | Press Release | $3.90 $4.54 | ▲ +16.41% | ▲ +8.55% | $2.13 (−45.41%) |
Mar 9, 2026 33w ago | Press Release | $3.91 $3.47 | ▼ −11.25% | ▼ −11.10% | $2.13 (−45.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers